Holen Sie sich die Stockscreener-App
14.14
1.43%
0.20
Beta Bionics Inc Aktie (BBNX) Neueste Nachrichten
Global Artificial Pancreas Devices Market is Gearing Up for Outstanding Expansion at a CAGR of ~16% by 2032 | DelveInsight - GlobeNewswire Inc.
Beta Bionics (NASDAQ:BBNX) Now Covered by Truist Financial - Defense World
Beta Bionics initiated with a Buy at Truist - TipRanks
Beta Bionics, Inc.: Strategic Growth and Market Penetration with iLet Infusion Pump - TipRanks
Beta Bionics stock initiated with Buy rating at Truist Securities By Investing.com - Investing.com South Africa
Beta Bionics stock initiated with Buy rating at Truist Securities - Investing.com
Lake Street Capital Initiates Coverage on Beta Bionics (NASDAQ:BBNX) - Defense World
Beta Bionics, Inc. (NASDAQ:BBNX) Receives $23.13 Average Price Target from Brokerages - Defense World
Beta Bionics Executives Unload Shares in Major Stock Sell-Off! - TipRanks
Beta Bionics CEO, CFO on how to take a company public - MedTech Dive
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Wolfe Research Initiates Coverage of Beta Bionics (BBNX) Stock with Outperform Rating - Insider Monkey
Beta Bionics (NASDAQ:BBNX) Now Covered by The Goldman Sachs Group - Defense World
Beta Bionics (NASDAQ:BBNX) Coverage Initiated by Analysts at Wolfe Research - Defense World
Goldman Sachs Initiates Coverage of Beta Bionics (BBNX) with Neutral Recommendation - Nasdaq
Goldman Sachs sets Beta Bionics stock at Neutral with $16 target - Investing.com Australia
Beta Bionics initiated with an Outperform at Wolfe Research - TipRanks
Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral - Asianet Newsable
Beta Bionics initiated with a Neutral at Goldman Sachs - TipRanks
The medtech IPO window is finally open. Or is it? - MedTech Dive
Diabetes Dialogue: Real-World Impact of iLet Bionic Pancreas, With Steven Russell, MD, PhD - HCPLive
Midday Stock Roundup: RxSight Up 13% on Wells Fargo Upgrade - Orange County Business Journal
Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc. - TipRanks
Transcript : Beta Bionics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Brokerages Set Beta Bionics, Inc. (NASDAQ:BBNX) Price Target at $24.83 - Defense World
Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism - TipRanks
Strong Performance and Growth Potential: Buy Rating for Beta Bionics, Inc. - TipRanks
Earnings call transcript: Beta Bionics Q1 2025 earnings miss estimates - Investing.com Australia
Earnings call transcript: Beta Bionics Q1 2025 earnings miss estimates By Investing.com - Investing.com UK
Positive Developments and Strong Financial Performance Drive Buy Rating for Beta Bionics, Inc. - TipRanks
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025 - GlobeNewswire
Beta Bionics Inc (BBNX) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ... By GuruFocus - Investing.com Canada
Beta Bionics Reports Strong Q1 2025 Results and Raises Guidance - TipRanks
Beta Bionics Q1 2025 slides: raised guidance despite earnings miss - Investing.com
Beta Bionics Q1 2025 slides: raised guidance despite earnings miss By Investing.com - Investing.com South Africa
Beta Bionics Q1 2025 Earnings Call Transcript - MarketBeat
Critical Review: Beta Bionics (NASDAQ:BBNX) and INVO Bioscience (NASDAQ:INVO) - Defense World
Beta Bionics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Highest quarter in years as med-tech raises $8B in Q1 financings - BioWorld MedTech
Beta Bionics to Present at the Bank of America Securities Health Care Conference - The Manila Times
Beta Bionics: Slowing Down Or Being Conservative? (NASDAQ:BBNX) - Seeking Alpha
Beta Bionics, Inc. (NASDAQ:BBNX) Receives $24.83 Average Target Price from Analysts - Defense World
beta bionics, inc., Earnings dates - RTTNews
Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Beta Bionics, Inc. to Release First Quarter 2025 Financial Results on May 6, 2025 - Nasdaq
0.54%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):